Back to Search
Start Over
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
- Source :
- The Journal of Allergy and Clinical Immunology: In Practice; 20210101, Issue: Preprints
- Publication Year :
- 2021
-
Abstract
- Benralizumab is an IL-5Rα–directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma.
Details
- Language :
- English
- ISSN :
- 22132198
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- The Journal of Allergy and Clinical Immunology: In Practice
- Publication Type :
- Periodical
- Accession number :
- ejs57664515
- Full Text :
- https://doi.org/10.1016/j.jaip.2021.07.058